What You Should Know:
– Mass General Brigham, a healthcare provider, and Annalise.ai, a global medical imaging AI company, today announced a strategic collaboration to develop and implement AI-enabled diagnostic products.
– This strategic partnership aims to leverage the complementary expertise and capabilities of both organizations to bring innovative AI solutions to the healthcare industry.RSNA News from GE HealthCare Announces SIGNA Champion & presence at RSNA23.
Core Pillars of Collaboration
The collaboration focuses on three core pillars: joint development and clinical validation of radiology products, extension into other diagnostic categories, and leveraging Annalise.ai’s AI solutions to enhance Mass General Brigham’s data assets for clinical and research missions. The collaboration will be executed through Mass General Brigham’s newly launched AI business office, which supports the development of AI-enabled software as medical device products from concept to clinical adoption.
FDA-Cleared Solution Deployment
Annalise.ai’s FDA-cleared worklist triage solution, Annalise Triage, is set to be deployed across Mass General Brigham’s system. The solution, with regulatory clearance in over 40 countries, automatically monitors chest X-ray (CXR) and non-contrast head CT (NCCTB) exams for critical findings, facilitating rapid alerts to clinicians.The collaboration builds upon a longstanding relationship between Mass General Brigham and Annalise.ai, which has resulted in 12 FDA-cleared chest X-rays and non-contrast head CT findings related to Annalise’s Triage product.
